Rubin Eyal 4
4 · Protalix BioTherapeutics, Inc. · Filed Sep 24, 2019
Insider Transaction Report
Form 4
Rubin Eyal
Sr. VP & CFO
Transactions
- Award
Stock Options (Right to Buy)
2019-09-22+800,000→ 800,000 totalExercise: $0.20Exp: 2029-09-22→ Common Stock (800,000 underlying)
Footnotes (1)
- [F1]The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.